etherna is an RNA technology company offering professional partnerships to pharma and biotech focused on RNA therapeutics. The expert team supports projects using proprietary platforms in RNA chemistry, LNP formulation, and Process Technology.

etherna

Domain Not Resolving

HSTS

IPv6

Cloudflare Hosting

Person Schema

jsDelivr

Cloudflare JS

CDN JS

Gravatar Profiles

HSTS IncludeSubdomains PreLoad

Director, Business Development (CMO)

David Ricketts

SVP - Chief Operational Officer

Bernard Sagaert

Operations

Alexandre Peeters

Principal Scientist Immuno-Oncology / Group Leader Immunomodulation Therapies

Florence Lambolez

Human Resources

Inne Van Hasselt

Senior Director Process Development & Qualified Person

Koen Huygens

Quality

Niels Delamotte

Marketing and Product

Catherine Reiter

Engineering

Maxim Feyaerts

Finance and Administration

Veronique Vandevenne

Marijn Dekkers

Kenneth Chien

Sonja Van Meirvenne

Quality Assurance & Regulatory Affairs

Dirk Reyn

Steffen Helmling

Chief Business Officer

Luc Lammens

Finance

Kris Thielemans

Founder and Chief Scientific Officer

Medical Device Early Stage Companies With Fewer Than 1000 Employees

Biotechnology Companies With More Than 50 Employees

European Union (EU) Health Care Companies (Top 10K)

Therapeutics Companies with Early Stage Venture Funding

etherna’s mission is to be a technology leader in the development of nucleic acid-based medicines which enables our partners to create new drugs and improve patients’ lives.

Novalis LifeSciences

Series B - etherna immunotherapies

European Commission

Grant - etherna immunotherapies

The Institute for the Promotion of Innovation by Science and Technology in Flanders

EQT Life Sciences

Series A - etherna immunotherapies

Niel

Antwerpen

Belgium

Europe

etherna immunotherapies

Global Oncology-based In-Vivo CRO Market is estimated to ...

Interim results from a phase I randomized, placebo-controlled ...

mRNA/LNP technology platform company etherna names ...

Steffen Helmling joins etherna as Chief Business Officer

Top 25 BioTech startups

Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation

RNA Therapeutics will explore industry insights into mRNA

Nutcracker raises $60M to fund 'push-button' mRNA therapeutics platform

Lipid nanoparticles (LNPs) are used for nucleic acid drug delivery, protecting the active payload from degradation and ensuring targeted delivery to the intended site of action.

Development of customized lipid nanoparticles (cLNPs) tailored for specific therapeutic applications, utilizing proprietary ionizable lipid libraries.

LNP formulations for systemic intravenous administration, designed to maximize T cell response and efficacy for systemic therapeutic vaccines.

LNP formulations for intra-tumoral administration, aimed at maximizing local mRNA expression in tumors while reducing off-target effects and inflammation.

LNP formulations for intramuscular administration, using novel ionizable lipids to maximize local mRNA expression with good tolerability and safety.

LNP formulations designed to induce immune tolerance against auto-antigens.

India

Asia

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 24, 2024 11:04 PM	aebcc791
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 24, 2024 11:04 PM	572ebe3a
crunchbase trigger	general	Dec 4, 2024 8:54 AM	9292fb48
crunchbase profile	general	Dec 4, 2024 1:29 PM	61047f98
li profile	general
translate crunchbase fundingrounds	general	Dec 4, 2024 1:59 PM	c58f30d3
peers	general	Oct 24, 2024 11:04 PM	ab2490aa
news basic	general	Oct 24, 2024 11:04 PM	6fb57061
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BE:ETHERNA

etherna